Efficacy of Vinblastine and Methotrexate in a Childhood Patient with Progressive Desmoid Fibromatosis of the Lower Jaw: A Case Report.

Q3 Medicine
Takashi Koike, Mayuko Shibata, Ryota Kaneko, Sachio Fujita, Kosuke Akiyama, Daisuke Toyama, Shohei Yamamoto
{"title":"Efficacy of Vinblastine and Methotrexate in a Childhood Patient with Progressive Desmoid Fibromatosis of the Lower Jaw: A Case Report.","authors":"Takashi Koike, Mayuko Shibata, Ryota Kaneko, Sachio Fujita, Kosuke Akiyama, Daisuke Toyama, Shohei Yamamoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Desmoid fibromatosis (DF) is defined as a borderline tumor of the soft tissues with a low malignant potential. The most common tumor sites are the extremity, trunk, abdominal cavity, and head and neck. Surgical resection has been the standard treatment for DF. However, there are concerns regarding long-term cosmetic outcomes or functional morbidity associated with surgery particularly in the head and neck. Recently, the use of the front-line wait-and-see strategy and pharmacologic treatment such as chemotherapy for progression has been proposed as tumors can spontaneously stabilize and regress. Herein, we report the efficacy of vinblastine (VBL) and methotrexate (MTX) in a childhood patients with DF. A 21-month-old female patient with a 4-cm tumor at the left lower jaw was diagnosed with DF. She did not initially receive any therapies (wait-and-see) according to the recent treatment guidelines. However, the tumor gradually progressed, and the patient was managed with COX2 inhibitor. Since the tumor was not controlled with such a treatment and tracheal exclusion caused by the mass was a cause of concern, the patient was managed with chemotherapy with VBL and MTX. VBL and MTX were administered weekly for 26 weeks, every other week, and further for 26 weeks. The tumor size gradually decreased with VBL and MTX. Magnetic resonance imaging revealed no evidence of the disease at the end of chemotherapy. Good cosmetic outcomes were achieved, and recurrence was not observed after 24 months of follow-up.</p>","PeriodicalId":38819,"journal":{"name":"Tokai Journal of Experimental and Clinical Medicine","volume":"49 4","pages":"137-139"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tokai Journal of Experimental and Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Desmoid fibromatosis (DF) is defined as a borderline tumor of the soft tissues with a low malignant potential. The most common tumor sites are the extremity, trunk, abdominal cavity, and head and neck. Surgical resection has been the standard treatment for DF. However, there are concerns regarding long-term cosmetic outcomes or functional morbidity associated with surgery particularly in the head and neck. Recently, the use of the front-line wait-and-see strategy and pharmacologic treatment such as chemotherapy for progression has been proposed as tumors can spontaneously stabilize and regress. Herein, we report the efficacy of vinblastine (VBL) and methotrexate (MTX) in a childhood patients with DF. A 21-month-old female patient with a 4-cm tumor at the left lower jaw was diagnosed with DF. She did not initially receive any therapies (wait-and-see) according to the recent treatment guidelines. However, the tumor gradually progressed, and the patient was managed with COX2 inhibitor. Since the tumor was not controlled with such a treatment and tracheal exclusion caused by the mass was a cause of concern, the patient was managed with chemotherapy with VBL and MTX. VBL and MTX were administered weekly for 26 weeks, every other week, and further for 26 weeks. The tumor size gradually decreased with VBL and MTX. Magnetic resonance imaging revealed no evidence of the disease at the end of chemotherapy. Good cosmetic outcomes were achieved, and recurrence was not observed after 24 months of follow-up.

文曲星和甲氨蝶呤对一名下颌骨进展性脱模性纤维瘤病儿童患者的疗效:病例报告。
脱模性纤维瘤病(DF)被定义为恶性程度较低的软组织边缘肿瘤。最常见的肿瘤部位是四肢、躯干、腹腔和头颈部。手术切除一直是 DF 的标准治疗方法。然而,人们对手术尤其是头颈部手术的长期美容效果或功能性发病率表示担忧。近来,由于肿瘤可自发稳定和消退,有人提出了一线观望策略和药物治疗(如化疗)来治疗进展期肿瘤。在此,我们报告了长春新碱(VBL)和甲氨蝶呤(MTX)对一名儿童 DF 患者的疗效。一名 21 个月大的女性患者被诊断出患有 DF,左下颌有一个 4 厘米的肿瘤。根据近期的治疗指南,她最初没有接受任何治疗(观望)。然而,肿瘤逐渐恶化,患者接受了 COX2 抑制剂治疗。由于这种治疗未能控制肿瘤,而且肿块引起的气管排异令人担忧,因此患者接受了 VBL 和 MTX 化疗。VBL和MTX每周一次,持续26周,然后隔周一次,再持续26周。肿瘤大小在 VBL 和 MTX 的作用下逐渐缩小。化疗结束时,磁共振成像显示没有任何疾病迹象。患者获得了良好的美容效果,随访24个月后未发现复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
32
期刊介绍: The Tokai Journal of Experimental and Clinical Medicine, also referred to as Tokai Journal, is an official quarterly publication of the Tokai Medical Association. Tokai Journal publishes original articles that deal with issues of clinical, experimental, socioeconomic, cultural and/or historical importance to medical science and related fields. Manuscripts may be submitted as full-length Original Articles or Brief Communications. Tokai Journal also publishes reviews and symposium proceedings. Articles accepted for publication in Tokai Journal cannot be reproduced elsewhere without written permission from the Tokai Medical Association. In addition, Tokai Journal will not be held responsible for the opinions of the authors expressed in the published articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信